StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.97−0.53 (-0.55%)

Close on Nov 17, 2026Market cap $10.89BP/E 28.3Yield –

Halozyme Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Halozyme Therapeutics's EV/EBITDA was 22.2× on Nov 11, 2026, against 12.7× a year earlier. Over the last 5 years it ranged from 12.0× to 35.3×, with a median of 19.8×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202622.2×+10.2
2025Dec 31, 202512.0×−3.2
2024Dec 31, 202415.2×−3.7
2023Dec 29, 202319.0×−16.2
2022Dec 30, 202235.1×+18.7
2021Dec 31, 202116.5×−126.3
2020Dec 31, 2020142.8×+102.5
2019Jan 31, 201940.2×+3.8
2018Dec 31, 201836.4×–

More Halozyme Therapeutics figures

See a number that looks wrong?